2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.17 Impact of Osimertinib and Cranial Therapy on EGFR-Mutated Lung Cancer with Brain Metastasis: A Single-institution Retrospective Study

EP.12A.17 Impact of Osimertinib and Cranial Therapy on EGFR-Mutated Lung Cancer with Brain Metastasis: A Single-institution Retrospective Study

Back to course

Pdf Summary

This single institution retrospective study explores the impact of the drug Osimertinib and cranial therapies on patients with Epidermal Growth Factor Receptor mutated (EGFRmt) non-small cell lung cancer (NSCLC) that has metastasized to the brain. Conducted at an academic institution from 2004 to 2023, the study primarily focuses on Osimertinib, a third-generation oral Tyrosine Kinase Inhibitor (TKI) known for its strong central nervous system (CNS) penetration and effectiveness.<br /><br />The study included predominantly female patients (68%), with a notable percentage of Asian descent (48%) and a median age of 66 years. Among these, 37% had a history of smoking. At diagnosis, 80% of the patients were classified as Stage IV, with CNS disease present in 69% of the cases.<br /><br />Key findings indicate that high-dose Osimertinib shows superior efficacy in controlling CNS disease compared to traditional chemotherapy in patients who experienced CNS progression. The study notes significant variability in treatment patterns following initial Osimertinib therapy. Despite the apparent success of Osimertinib, especially in leptomeningeal disease, there remains a lack of standardized guidelines for its high-dose application.<br /><br />The study concludes by emphasizing the durable efficacy of Osimertinib over other EGFR TKIs in treating CNS metastases in EGFRmt NSCLC. Furthermore, it highlights the need for prospective studies to establish standardized treatment protocols, considering the promising outcomes noted in the study.<br /><br />The authors acknowledge the complexities surrounding CNS management due to the multimodal approach and the absence of specific guidelines, urging further research to optimize combination strategies with radiation therapy for varied EGFR mutations.

Asset Subtitle

Christine Garcia

Meta Tag

Speaker Christine Garcia

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

Osimertinib

EGFRmt

NSCLC

brain metastasis

CNS penetration

Tyrosine Kinase Inhibitor

leptomeningeal disease

high-dose application

treatment protocols

radiation therapy